Tolimidone Chemical Properties

Melting point:

163-164℃

Density 

1.22

storage temp. 

room temp

solubility 

DMSO: soluble15mg/mL (clear solution)

form 

powder

pka

8.14±0.10(Predicted)

color 

white to beige

Safety Information

Hazard Codes 

Xi

Risk Statements 

36

Safety Statements 

26

WGK Germany 

3

Tolimidone Usage And Synthesis

Description

MLR-1023 is an allosteric activator of Lyn kinase (EC₅₀ = 63 nM). It has no significant activity against a panel of related kinases. MLR-1023 is orally bioavailable and reduces blood glucose levels in mice subjected to an oral glucose tolerance test. This effect is insulin-dependent, with MLR-1023 increasing insulin receptor sensitivity. MLR-1023 produces a dose-dependent and durable glucose-lowering effect in chronically treated db/db mice without causing weight gain.

Uses

Tolimidone (MLR-1023) is an allosteric Lyn kinase activator that has been shown to reduce blood glucose levels in mice. Studies show that Tolimidone is an effective insulin receptor-potentiating agent that is potentially capable of producing durable blood glucose-lowering activity in diabetics. Tolimidone is a candidate for the treatment of type 2 diabetes.

in vivo

storage

Store at +4°C

References

[1] MICHAEL S SAPORITO. MLR-1023 is a potent and selective allosteric activator of Lyn kinase in vitro that improves glucose tolerance in vivo.[J]. ACS Applied Electronic Materials, 2012: 15-22. DOI: 10.1124/jpet.112.192096
[2] ALEXANDER R OCHMAN. The Lyn kinase activator MLR-1023 is a novel insulin receptor potentiator that elicits a rapid-onset and durable improvement in glucose homeostasis in animal models of type 2 diabetes.[J]. Journal of Pharmacology and Experimental Therapeutics, 2012, 342 1: 23-32. DOI: 10.1124/jpet.112.192187

Tolimidone(41964-07-2)Related Product Information

• Mifepristone
• Tolimidone
• 2(1H)-Pyrimidinone, 5-methoxy- (9CI)